Improving how the system introduces novel therapies

After a lipid lowering treatment for people with CVD in GM was introduced it was evident that there were inconsistencies in the way the medication was recorded on a patient’s record. This meant it was difficult to fully evaluate the impact of the new medication. Work was undertaken with stakeholders in primary care to gain feedback on how this could be prevented in the future.

A blueprint is now being developed that outlines what steps need to be taken to ensure the future introduction of any novel therapy in GM is a seamless transition.

This work will also involve reviewing how new medications need to be coded when added to a patient’s record to ensure the information is done in a clear and consistent way to support a successful introduction of it.